**2.6. Sunitinib**

Sunitinib is another orally active multi-kinase inhibitor that targets a variety of tyrosine kinases in addition to VEGFR, including PDGFRs, KIT, RET, and FMS-like tyrosine kinase 3 (FLT3) [17].

Sunitinib was significantly inferior to sorafenib in a phase III trial that directly compared both drugs in 1073 previously untreated patients with advanced HCC [18]. The trial was closed prematurely when an interim analysis revealed that patients receiving sunitinib had significantly worse survival (median 7.9 vs. 10.2 months) and more frequent and severe treatmentrelated toxicity.
